Search. Read. Cite.

Easy to search. Easy to read. Easy to cite with credible sources.

Research Article
Clinical Significance and Potential Utility of Cancer Stem Cell Markers: ALDH1A1 and CD133 in Prostate Tumors

Hassan Fouad Huwait, Anmar Mohammed Nassir, Hanan Mohamed Abd Elmoneim, Hala Fawzy Mohamed Kamel, Nisreen Dahi Toni, Nada Adel Babtain, Alaa Sami Barhamain, Abdul Basit Sadiq Malibari, Shrouk Fares Munassar, Raneem Sami Rawa and Ashwak Zahed Kufiah

International Journal of Cancer Research, 2018, 14(1), 39-51.

Abstract

Background and Objectives: Cancer stem cells (CSCs) have been shown to be associated with initiation of some prostate tumors with redirection towards cancer progression, metastasis and resistance to treatment. Therefore, evaluation of such markers for CSCs as aldehyde dehydrogenase (ALDH1A1) and CD133 may help in improving treatment modalities and better survival rates. Current study aimed to explore the clinical significance of expression levels of CSCs related markers: ALDH1A1 and CD133 in relation to other markers as androgen receptor (AR), prostate specific antigen and clinicopathological parameters in series of prostate tumors. Materials and Methods: Eighty-four male patients with prostate tumors recruited in this study, they included [n = 35] benign prostatic hyperplasia (BPH), [n = 17] prostatic intraepithelial neoplasia (PIN) and [n= 32] prostate cancer (PCa). Pre-operative blood samples examined for PSA by enzyme immunoassay and formalin-fixed paraffin-embedded archival blocks were assessed by immunohisto-chemical for expression of ALDH1A1, CD133 and AR, using avidin biotin-peroxidase complex method. Markers expression assessed microscopically and the data were analyzed and correlated with clinicopathological parameters. In addition, Kaplan Meier survival analysis was used to estimate overall survival of the patients. Results: Expression of ALDH1A1 levels were significantly higher in prostate cancer in comparison to both prostatic intraepithelial neoplasia and benign prostatic hyperplasia (p<0.001) while, CD133 expression showed statistically significant difference in between the three studied groups (p = 0.001). None of benign prostatic hyperplasia cases showed a high level of CD133 expression and (85.7%) of them showed negative expression of ALDH1A1. Expression of ALDH1A1 and CD133 showed positive significant correlation with prostate specific antigen and most of the studied clinicopathological parameters of prostate cancer, however, no correlation was found between CD133 expression and Gleason score. Joint expression of ALDH1A1 and CD133 had a significantly worse prognosis than the other groups (p<0.001) and is predictive of short survival duration. Conclusion: Joint detection of ALDH1A1 and CD133 helps in early diagnosis, prevention and improve predictions of prognosis for prostate tumors with better discrimination.

ASCI-ID: 36-319

Cited References Fulltext

Related Articles


Regulation of Cancer Stem Cell Marker (CD133) by Transforming Growth Factor Beta in Hepatocellular Carcinoma

International Journal of Cancer Research, 2014, 10(2), 65-73.

Expression of Vascular Endothelial Growth Factor Protein in Both Serum Samples and Excised Tumor Tissues of Breast Carcinoma Patients

International Journal of Cancer Research, 2016, 12(3-4), 152-161.

Nuclear and Cytoplasmic Expression of Survivin in Breast Carcinoma: Correlation with Clinicopathological Parameters

International Journal of Cancer Research, 2016, 12(3-4), 128-139.